Page 15 - Solid Biosciences News Today

/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...

/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...

10/01/21 Life Science Leader Newsletter

Ogilvy and McCann heavyweight Andrew Schirmer has joined Syneos Health's GSW New York as president. Three members of the FDA panel that argued against aducanumab have quit in the wake of the Alzheimer's drug's approval. Inogen, recently equipped with a new CEO, has tapped BD vet Stanislav Glezer, M.D., as its chief medical officer.

Dive Brief: Sarepta Therapeutics on Tuesday disclosed results from a small but important study, showing a commercial-grade version of its gene therapy for Duchenne muscular dystrophy appears comparable to the product it used in earlier clinical testing. The first 11 patients to receive the commercial version of the therapy produced an average of 55.4% of normal levels of "micro" dystrophin — a shortened form of the protein Duchenne patients lack — three months after treatment. That number w...

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences update call. [Operator instructions] Please be advised that todays conference is being recorded. I would now like to hand the conference over to your speaker today, Mr. Tim Palmer, corporate communications manager at Solid Biosciences. Sir, you may begin. Corporate Communications Manager Good morning. Thank you, operator. Before we get started, I would like to remind everyone that during this conferen...

• Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its first quarter. • Diversey Holdings (NASDAQ:DSEY) is likely to report quarterly earnings at $0.04 per share on revenue of $616.76 million. • Solid Biosciences (NASDAQ:SLDB) is projected to report earnings for its second quarter. • Vasta Platform (NASDAQ:VSTA) is expected to report earnings for its first quarter. • Fangdd Network Group (NASDAQ:DUO...

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latters investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in... Read More...

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet...

These drugmaker stocks may have been hammered down to bargain-bin prices.